Williams-Sonoma, Inc. (WSM)’s Stock Plummets After Weak Guidance For The Coming Quarter

Williams-Sonoma, Inc. (NYSE:WSM), the California-headquarter specialty home furnishings retailer, had yesterday released its earnings report for the second quarter, ended on August 3. Sales revenue amounted to $1.04 billion, which was 5.8% higher compared to the same period of last year and only slightly smaller than market estimate of $1.05 billion. Meeting revenue targets notwithstanding a lower than expected guidance for the third quarter caused the company’s shares to take a plunge, which fell by more than 11.2%. For the third quarter, the company expects revenue between $1.1 billion to $1.13 billion and diluted EPS from $0.58 to $0.63. David Magee, Analyst at SunTrust Robinson Humphrey talked about this and the issues faced by retailers this summer on CNBC’s Squawk Box.

Williams-Sonoma, Inc. (NYSE:WSM)

Magee felt that Williams-Sonoma, Inc. (NYSE:WSM) stock had been doing too good this quarter. It was up by almost 10 % in the recent weeks and that was one of the major reasons why the company was able to meet the market estimate.

“[...] The stock had done so good recently, it got ahead of itself, stock is up almost 10% in recent weeks and so they hit the number, they would have beaten the number had it not been for a higher tax rate [...],” he said explaining about the unexpected tax rate which was responsible for the revenue falling slightly short of the market consensus.

As a retailer, Williams-Sonoma, Inc. (NYSE:WSM) had the option to adjust its pricing and catalog depending on the situation. The second quarter’s gross margin line reflected the retailer’s reduction in pricing as it was a tough summer for retailers all over. Though this was not a permanent situation, it must be approached with caution as it had a tendency to affect the value of the stock.

“We’ve seen this in the past and that is not a permanent condition but it does cause volatility in the stock,” observed Magee.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!